Quebec platelet disorder (QPD), 286-287 R

Radionuclide scanning, Hodgkin disease, 470 Radiotherapy cardiovascular system, late effects of childhood cancer, 756

central nervous system, late effects of childhood cancer, 759-762, 761t endocrine system, late effects of childhood cancer, 764-766, 7651, 767t hepatoma, 666

musculoskeletal system, late effects of childhood cancer, 749, 753, 753t Non-Hodgkin lymphoma, 508 ovarian dysgerminoma, 653-654 regimens for initial cycle of, 7411 respiratory system, late effects of childhood cancer, 757 retinoblastoma episcleral plaque, 638 external beam, 637-638 rhabdomyosarcoma, 570-571, 571t RB1 gene mutations. See Retinoblastoma in osteosarcoma, 586 R-binder deficiency, 52, 531, 56t Recombinant factor VII (rFVIIa), treatment in hemophilia, 318t, 319 Red blood cells. See also Erythrocytes, abnormal failure of production acquired, viral diseases, 27 congenital, 14t, 27 impaired red cell formation, 2t indications for small-volume RBC transfusion in preterm infants, 27, 28t in iron-deficiency anemia, 37-38t morphologic abnormalities in anemia, 5-7t nucleated, 7t zinc protoporphyrin/heme ratio, in iron deficiency, 40 Red cell distribution width (RDW), 9t Red cell values and related serum values, 775-785

blood volumes, estimated, 7831

enzyme activities and glutathione content in newborn and adult red blood cells, 785t on first postnatal day, 776t hemoglobin and MCV percentile curves, 779/ hemoglobin and reticulocyte values for term and preterm infants, 778/ hemoglobin concentrations for iron-sufficient preterm infants, 775t hemoglobin F

and A2, percentage in newborn and adult,

7822t percentage in first year of life, 782t relative concentration according to age, 783t hemoglobin values in first 2 weeks of life, 776t methemoglobin levels in normal children, 784t normal serum folic acid levels, 7821 serum erythropoietin levels, 784t serum ferritin values, 780t serum iron, total iron-binding capacity, and transferrin saturation during first year of life, 7811

serum iron and iron saturation percentage, 781t serum iron and transferrin saturation values, 780/

at various ages: mean and lower limit of normal, 777t Reed-Sternberg cells, 456-458, 457t Renal artery thrombosis, 335 Renal disease benefits of recombinant human erythropoietin in children with, 751 clear cell sarcoma, 559 hematologic manifestations, 74-75 hypoplastic kidney, late effects of childhood cancer, 768-769 late effects of childhood cancer, 768-769 renal cell carcinoma, 559-560 rhabdoid tumor of, 559 Renal failure, platelet disorders and, 289 Renal manifestations, with Hodgkin disease, 464 Renal toxicity, prevention of, 728 Respiratory burst oxidase, 231 Respiratory burst pathway, reactions, 231, 232t Respiratory system, late effects of childhood cancer, 757-759, 758t Reticular dysgenesis, 216-217t Reticulocyte count in anemia, 1, 8/, 9 in iron deficiency anemia, 38 Reticulocyte index, 9 Retinoblastoma, 630-643 classification focality, 631 genetics, 631-633 genetic counseling, 632 hereditary retinoblastoma, 631-632 nonhereditary retinoblastoma, 632 prenatal diagnosis, 632 RB1 gene, 631

two-hit hypothesis (Knudson), 631 international classification system for intraocular retinoblastoma, 637t laterality, 631

Retinoblastoma (Continued) clinical features patterns of spread, 634 presenting signs and symptoms, 634 trilateral retinoblastoma, 634-635 diagnostic procedures, 635, 636t epidemiological data, 632-633 future perspectives, 642-643, 643t incidence, 630 pathology retinoblastoma, 633-634 retinocytoma, 634 post-treatment management disease-related follow-up, 640-641 toxicity-related follow-up, 641, 642t Reese-Ellsworth staging for intraocular retinoblastoma, 635, 636t second malignant neoplasms, risk for, 633 staging, 635-636t treatment of extraocular retinoblastoma, 639-640, 640t of intraocular retinoblastoma, 637-639, 637t of recurrent retinoblastoma, 640 Retinocytoma, 634 Retinopathy, in SCD, 166-167 Rh isoimmunization clinical features, 17-18t, 19 laboratory findings, 19 management antenatal, 19-23, 21f, 22f postnatal, 24 prevention, 24 Rhabdoid tumor, of kidney, 551t, 559 Rhabdomyosarcoma (RMS), 561-583

assays used in the differential diagnosis of, 564

clinical features primary sites, 565, 566t signs and symptoms, 565, 566-567t, 567 diagnostic evaluation, 567-568 epidemiology, 561 examinations in special sites, 568 genetics of clinical genetic factors, 565 molecular genetics, 565 histologic subtypes, 564t nonrhabdomyosarcoma soft-tissue sarcomas

(NRSTS), 561, 562-563t pathologic classification, 564

histologic subtypes, 564t prognosis age, 580

cellular DNA (ploidy), 581 extent of disease, 579 failure-free survival at 3 years according to histologic subtype, 580t by stage and group on IRS-IV, 580t histologic and cytologic type, 580t primary tumor site, 580 recurrent disease, 581-583, 582t recurrent soft-tissue sarcomas, 582t response to therapy, 581

risk stratification and survival data fro IRS-III and IRS-IV, 5811

sites of metastases, 5811 tumor burden at diagnosis, 580 staging, 568-569

Intergroup Rhabdomyosarcoma Study (IRS), 569t

TNM staging system, 569t treatment chemotherapy, 571, 572-573t, 574f, 575f, 576f, follow-up after completion of therapy,

578-579 future perspectives for, 583 radiotherapy, 570-571, 571t for specific anatomic sites bladder neck/trigone and prostate, 578 extremities, 571t, 573t, 577 genitourinary tract, 572-573t, 578 head and neck (extraorbital), 571, 572t,

574, 575f, 576f orbit and eyelid, 5721, 574, 574f paratesticular lesions, 571f, 574, 576-577, 5721, retroperitoneal area, 573t, 577-578 vagina, uterus, and bladder dome, 578, 5721 surgery, 570

Rituximab, immune thrombocytopenia, 261-262 Rizzoli's 4th protocol for osteosarcoma, 591, 593, 593f

RMS. See Rhabdomyosarcoma (RMS) Rosai-Dorfman disease, 608, 626

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment